Trial Profile
A 24 week Prospective Non-Interventional Post-Marketing Surveillance Study on Adverse Events and Serious Adverse Events in Patients with Type 2 Diabetes Mellitus in India being started on Dulaglutide (Trulicityâ?¢)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 05 Nov 2019 Status changed from not yet recruiting to recruiting.
- 13 Nov 2018 New trial record